Curi RMB Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Curi RMB Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$540K	Sell	9,442 -3,800	-29%	-$208K	0.01%	585
2026 Q1	$748K	Sell	13,242 -695	-5%	-$40.5K	0.01%	506
2025 Q4	$828K	Buy	+13,937	New	+$759K	0.01%	496
2023 Q3	–	Sell	-3,540	Closed	-$307K	–	500
2023 Q2	$307K	Hold	3,540	–	–	0.01%	431
2023 Q1	$344K	Hold	3,540	–	–	0.01%	411
2022 Q4	$366K	Buy	3,540 +140	+4%	+$13.1K	0.01%	395
2022 Q3	$288K	Hold	3,400	–	–	0.01%	409
2022 Q2	$282K	Hold	3,400	–	–	0.01%	417
2022 Q1	$262K	Hold	3,400	–	–	0.01%	405
2021 Q4	$300K	Hold	3,400	–	–	0.01%	402
2021 Q3	$263K	Hold	3,400	–	–	0.01%	409
2021 Q2	$284K	Hold	3,400	–	–	0.01%	418
2021 Q1	$257K	Hold	3,400	–	–	0.01%	415
2020 Q4	$298K	Hold	3,400	–	–	0.01%	499
2020 Q3	$259K	Sell	3,400 -738	-18%	-$74.7K	0.01%	522
2020 Q2	$510K	Buy	4,138 +738	+22%	+$73.3K	0.02%	402
2020 Q1	$287K	Sell	3,400 -14	-0.4%	-$1.21K	0.01%	499
2019 Q4	$289K	Hold	3,414	–	–	0.01%	562
2019 Q3	$230K	Sell	3,414 -283	-8%	-$21.8K	0.01%	641
2019 Q2	$317K	Hold	3,697	–	–	0.01%	621
2019 Q1	$328K	Buy	3,697 +148	+4%	+$13.7K	0.01%	654
2018 Q4	$302K	Sell	3,549 -200	-5%	-$19K	0.01%	743
2018 Q3	$364K	Sell	3,749 -2	-0.1%	-$200	0.01%	689
2018 Q2	$353K	Buy	3,751 +202	+6%	+$17.7K	0.01%	687
2018 Q1	$288K	Buy	3,549 +60	+2%	+$5.15K	0.01%	739
2017 Q4	$311K	Buy	+3,489	New	+$303K	0.01%	708
2017 Q2	–	Sell	-6,300	Closed	-$553K	–	726
2017 Q1	$553K	Buy	+6,300	New	+$560K	0.02%	361

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Curi RMB Capital's BMRN Position: Q2 2026 in Review

Curi RMB Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 29% in Q2 2026, selling an estimated $208K and leaving 9,442 shares worth $540K. The position accounts for 0.01% of the portfolio, ranked #585.

Curi RMB Capital first reported a position in BMRN in Q1 2017 and has held it in 27 quarters since. The position peaked at $828K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Curi RMB Capital held 9,442 shares of BioMarin Pharmaceuticals worth $540K as of Q2 2026.
Curi RMB Capital sold 3,800 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $208K.
BioMarin Pharmaceuticals made up 0.01% of Curi RMB Capital's portfolio in Q2 2026, its #585 holding.
Curi RMB Capital first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 27 quarters since.
Curi RMB Capital's BioMarin Pharmaceuticals position peaked at $828K in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Curi RMB Capital's 13F filing for Q2 2026, filed 14 Aug 2026.